Marieke van der Zwan
Overview
Explore the profile of Marieke van der Zwan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
78
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
van Vugt L, Tegzess E, van der Zwan M, Clahsen-van Groningen M, de Winter B, Vart P, et al.
Clin Transplant
. 2024 Dec;
38(12):e70046.
PMID: 39636744
Background: Alemtuzumab can be an alternative to rabbit anti-thymocyte globulin (rATG) to treat severe or glucocorticoid-resistant acute T cell-mediated kidney transplant rejection (TCMR). Yet, there are few reports in which...
2.
van Vugt L, van der Zwan M, Clahsen-van Groningen M, van Agteren M, Hullegie-Peelen D, de Winter B, et al.
Transpl Int
. 2023 Nov;
36:11834.
PMID: 38020744
Alemtuzumab is used as lymphocyte-depleting therapy for severe or glucocorticoid-resistant kidney transplant rejection. However, the long-term efficacy and toxicity of alemtuzumab therapy are unclear. Therefore, all cases of alemtuzumab anti-rejection...
3.
Hullegie-Peelen D, van der Zwan M, Clahsen-van Groningen M, Mustafa D, Baart S, Reinders M, et al.
Clin Pharmacol Ther
. 2022 Feb;
111(5):1155-1164.
PMID: 35202481
Alemtuzumab, a monoclonal antibody that depletes CD52-bearing immune cells, is an effective drug for the treatment of severe or glucocorticoid-resistant acute kidney transplant rejection (AR). Patient-specific predictions on treatment response...
4.
van der Zwan M, Hesselink D, Baan C, Clahsen-van Groningen M
Transplantation
. 2020 Aug;
105(3):478-479.
PMID: 32732617
No abstract available.
5.
Comparison of Alemtuzumab and Anti-thymocyte Globulin Treatment for Acute Kidney Allograft Rejection
van der Zwan M, Clahsen-van Groningen M, van den Hoogen M, Kho M, Roodnat J, Mauff K, et al.
Front Immunol
. 2020 Jul;
11:1332.
PMID: 32719676
Rabbit anti-thymocyte globulin (rATG) is currently the treatment of choice for glucocorticoid-resistant, recurrent, or severe acute allograft rejection (AR). However, rATG is associated with severe infusion-related side effects. Alemtuzumab is...
6.
van der Zwan M, Leebeek F, Sandberg Y, Kruip M, Hesselink D
Haemophilia
. 2020 Jul;
26(6):e337-e339.
PMID: 32700327
No abstract available.
7.
van der Zwan M, Hesselink D, Brusse E, van Doorn P, van den Hoogen M, de Weerd A, et al.
Neurol Neuroimmunol Neuroinflamm
. 2020 Apr;
7(4).
PMID: 32299841
No abstract available.
8.
Snijders M, Varol H, van der Zwan M, Becker J, Hesselink D, Baan C, et al.
Transplantation
. 2020 Mar;
104(12):2478-2486.
PMID: 32150035
A renal core biopsy for histological evaluation is the gold standard for diagnosing renal transplant pathology. However, renal biopsy interpretation is subjective and can render insufficient precision, making it difficult...
9.
van der Zwan M, Hesselink D, van den Hoogen M, Baan C
Drugs
. 2019 Nov;
80(1):33-46.
PMID: 31749062
Costimulation between T cells and antigen-presenting cells is essential for the regulation of an effective alloimmune response and is not targeted with the conventional immunosuppressive therapy after kidney transplantation. Costimulation...
10.
van der Zwan M, Hesselink D, Clahsen-van Groningen M, Baan C
Ther Drug Monit
. 2019 Mar;
41(2):243-248.
PMID: 30883517
Background: There is an unmet need for reliable minimally invasive diagnostic biomarkers for immunological allograft monitoring and for the detection of acute kidney transplant rejection. Here, targeted proteomic analysis was...